Stay updated on Avelumab in 3rd-Line Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Avelumab in 3rd-Line Gastric Cancer Clinical Trial page.

Latest updates to the Avelumab in 3rd-Line Gastric Cancer Clinical Trial page
- Check3 days agoChange DetectedThe study page now shows a 403 Forbidden error with an '403 Forbidden' page, replacing the previous study record content. This means the trial details and related information are no longer accessible on this page.SummaryDifference19%

- Check9 days agoChange DetectedA new revision tag was added (Revision: v3.7.0), replacing the previous Revision: v3.6.6 to indicate a version update.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe site underwent a small frontend revision, upgrading from v3.6.5 to v3.6.6, indicating an incremental update to the interface and internal components rather than substantive changes to study details.SummaryDifference0.0%

- Check31 days agoChange DetectedAdded a line in the Study Details noting the 2015 NIH grant/contract, linking the study to NIH funding information.SummaryDifference0.0%

- Check45 days agoChange DetectedA new revision tag, v3.6.5, was added to the page, replacing the previous v3.6.4 and signaling a small update to the page's versioning.SummaryDifference0.0%

- Check66 days agoChange DetectedThe revision label on the page updated from v3.6.3 to v3.6.4, representing a small update to the page metadata. This change does not modify the study details or other content visible to users.SummaryDifference0.0%

Stay in the know with updates to Avelumab in 3rd-Line Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avelumab in 3rd-Line Gastric Cancer Clinical Trial page.